Biogen Inc.: New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
Biogen Inc.: New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus (ocrelizumab) (diroximel fumarate) reinforce the treatment's positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab CAMBRIDGE, Mass., April 16, 2021(Nasdaq: BIIB) today announc...